ArticleCell2020
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 431 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
431citing papers in PubMed, 2 pooled it
25.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
431 citing papers in PubMed, 2 syntheses or guidelines pooled it, 614 citations in OpenAlex.
- Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review.Journal of translational medicine · 2025Pooled it
- PI3K/AKT/mTOR Targeting in Colorectal Cancer Radiotherapy: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer.Science advances · 2026Trial
- Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.Journal for immunotherapy of cancer · 2025Trial
- Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Breast cancer research and treatment · 2025Trial
- Reprogramming tumor-associated macrophages in breast cancer: from myeloid plasticity and tumor-promoting programs to CAR-macrophage therapy.Journal of hematology & oncology · 2026Review
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Context-dependent TREM2 signalling in myeloid cells: Molecular mechanisms and immunotherapeutic divergence in neurodegeneration and cancer.Clinical and translational medicine · 2026Review
- Pan-cancer epigenetic landscape of human tumor-associated macrophages reveals crucial enhancers governing their heterogenous formation by Pol II pausing modulation.Journal of advanced research · 2026Article
- A pancreatic cancer organoid-macrophage co-culture using starPEG-heparin hydrogel deciphers tumor-immune cell interactions.NPJ precision oncology · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- Spatial and Temporal Heterogeneity of Macrophage Efferocytosis in Tumors: Emerging Implications for Immunotherapy Biomarkers and Therapeutic Timing.Cancer medicine · 2026Review
- Uncovering the biological mechanisms of TREM2 with molecular simulations: A comprehensive review and perspective.Progress in biophysics and molecular biology · 2026Review
- Heterogeneous Expression of TREM2 And STAB1 Among Tumor-Associated Macrophages in Clear-Cell Renal Cell Carcinoma.Acta histochemica et cytochemica · 2026Article
- Review
- XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer.Nature communications · 2026Article
- Review
- Driving tumor-associated macrophages to a CXCL9Cell reports. Medicine · 2026Article
- Macrophage Plasticity in Cancer Therapy: Function, Timing, and Tradeoffs.International journal of molecular sciences · 2026Review
371 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
21 authors at 5 institutions in 2 countries.
Martina MolgoraDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Ekaterina EsaulovaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
William VermiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology, University of Brescia, Brescia 25123, Italy.
Jinchao HouDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Yun ChenDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Jingqin LuoDivision of Public Health Sciences, Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, MO 63110, USA.
Simone BrioschiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Mattia BugattiDepartment of Pathology, University of Brescia, Brescia 25123, Italy.
Andrea Salvatore OmodeiDepartment of Pathology, University of Brescia, Brescia 25123, Italy.
Biancamaria RicciDepartment of Orthopedics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Catrina FronickMcDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO 63108, USA.
Santosh K PandaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Yoshiko TakeuchiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Matthew M GubinDepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roberta FaccioDepartment of Orthopedics, Washington University School of Medicine, St. Louis, MO 63110, USA; Shriners Children's Hospital in St. Louis, St. Louis, MO 63110, USA.
Marina CellaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Susan GilfillanDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Emil R UnanueDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Maxim N ArtyomovDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Robert D SchreiberDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
Marco ColonnaDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: mcolonna@wustl.edu.
Washington University in St. Louis · USUniversity of Brescia · ITJames S. McDonnell Foundation · USSt. Louis Children's Hospital · USThe University of Texas MD Anderson Cancer Center · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MDIABETOGENIC MOLECULE I-AG7--CHEMISTRY AND BIOLOGYR01DK058177 · NIDDK · WASHINGTON UNIVERSITY · PI UNANUE, EMIL RAPHAEL · 2000 to 2020
$7.8MTREM2 IN MICROGLIA BIOLOGY AND ALZHEIMER'S DISEASERF1AG051485 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2015 to 2021
$3.5MTHERAPEUTIC STRATEGIES FOR ALZHEIMER'S DISEASE BASED ON TREM2 BIOLOGYRF1AG059082 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2019 to 2019
$2.6MDEVELOPMENT OF GENOMICS BASED PERSONALIZED CANCER IMMUNOTHERAPYR01CA190700 · NCI · WASHINGTON UNIVERSITY · PI SCHREIBER, ROBERT DAVID · 2015 to 2019
$2.1MAUTOIMMUNE DIABETES: EARLY EVENTS IN ISLETS OF LANGERHANSR01AI114551 · NIAID · WASHINGTON UNIVERSITY · PI UNANUE, EMIL RAPHAEL · 2015 to 2019
$2.1MNovel Regulators of Inflammatory Arthritis and Bone ErosionR01AR066551 · NIAMS · WASHINGTON UNIVERSITY · PI FACCIO, ROBERTA · 2015 to 2020
$2.0MRole of Bone in Primary and Metastatic CancerR01CA235096 · NCI · WASHINGTON UNIVERSITY · PI FACCIO, ROBERTA · 2020 to 2024
$1.8MIMPACT OF NOVEL REGULATORS OF TREM2 EXPRESSION ON ALZHEIMER'S DISEASER21AG059176 · NIA · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2018 to 2019
$419kNCI NIH HHS P30 CA091842NCI NIH HHS R01 CA190700NCI NIH HHS R01 CA235096NIAID NIH HHS R01 AI114551NIAMS NIH HHS R01 AR066551NIA NIH HHS R21 AG059176NIA NIH HHS RF1 AG051485NIA NIH HHS RF1 AG059082NIDDK NIH HHS R01 DK058177
Abstract
Checkpoint immunotherapy unleashes T cell control of tumors, but is undermined by immunosuppressive myeloid cells. TREM2 is a myeloid receptor that transmits intracellular signals that sustain microglial responses during Alzheimer's disease. TREM2 is also expressed by tumor-infiltrating macrophages. Here, we found that Trem2
Indexed as
ImmunotherapyAnimalsAntibodies, MonoclonalCell Line, TumorCX3C Chemokine Receptor 1Disease Models, AnimalHumansLymphocytes, Tumor-InfiltratingMembrane GlycoproteinsMethylcholanthreneMiceMice, Inbred C57BLMice, KnockoutNeoplasmsPrognosisProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalCX3C Chemokine Receptor 1Cx3cr1 protein, mouseMembrane GlycoproteinsMethylcholanthreneMRC1 protein, mouseProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTrem2 protein, mousebreast cancercheckpoint blockadecolorectal cancerhumanmacrophagessarcomaTREM2tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.